Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases—the IKF-080/AIO-QUINTIS trial

Background: Patients with metastatic colorectal cancer (mCRC) who have progressed on fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic agents, and anti-epidermal growth factor receptor (EGFR) therapies have limited treatment options and poor prognosis, with a median overall survival (mOS)...

Celý popis

Podrobná bibliografie

Hlavní autoři:	J. Tintelnot, J. Gorgulho, S.-E. Al-Batran, D. Arnold, A. Reinacher-Schick, S. Kasper, G. Prager, T. Goetze, R. Boston, M.S. Cruz, F. Dierks, A. Stein
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-03-01
Edice:	ESMO Gastrointestinal Oncology
Témata:	MSS mCRC non-liver-metastases checkpoint inhibition fruquintinib tislelizumab
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2949819826000129
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!